Madrigal Pharmaceuticals (MDGL) – Analysts’ Weekly Ratings Updates

A number of research firms have changed their ratings and price targets for Madrigal Pharmaceuticals (NASDAQ: MDGL):

• 5/13/2026 – Madrigal Pharmaceuticals had its price target raised by Truist Financial Corporation from $640.00 to $709.00. They now have a “buy” rating on the stock.
• 5/7/2026 – Madrigal Pharmaceuticals was given a new $649.00 price target by Evercore Inc.
• 5/7/2026 – Madrigal Pharmaceuticals had its price target lowered by Canaccord Genuity Group Inc. from $587.00 to $578.00. They now have a “buy” rating on the stock.
• 5/6/2026 – Madrigal Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $620.00 price target on the stock.
• 4/21/2026 – Madrigal Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling at Madrigal Pharmaceuticals

In other news, CEO William John Sibold sold 1,663 shares of Madrigal Pharmaceuticals stock in a transaction on Friday, March 6th. The shares were sold at an average price of $431.94, for a total transaction of $718,316.22. Following the completion of the sale, the chief executive officer directly owned 161,829 shares in the company, valued at approximately $69,900,418.26. The trade was a 1.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider David Soergel sold 844 shares of Madrigal Pharmaceuticals stock in a transaction on Monday, May 18th. The stock was sold at an average price of $515.90, for a total transaction of $435,419.60. Following the sale, the insider owned 11,075 shares of the company’s stock, valued at $5,713,592.50. The trade was a 7.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 6,942 shares of company stock valued at $3,061,673. Company insiders own 17.60% of the company’s stock.

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.